Cardiac events remain the leading cause of peri-operative morbidity and mortality, and patients undergoing major surgery are exposed to significant risks which may be preventable and modifiable. Proper assessment and management of various cardiac conditions in the peri-operative period by anaesthetists can markedly improve patient safety, especially in high-risk patient populations. This involves understanding and applying current evidence-based practice and international guidelines on the main aspects of cardiac optimisation, including management of patients with hypertension, chronic heart failure, valvular heart diseases and cardiac implantable electronic devices. Peri-operative management of antihypertensive drugs in keeping with the current best evidence is discussed. Pre-operative cardiac risk assessment and cardiac biomarkers can be used to help predict and quantify peri-operative adverse cardiac events. There is an increasing need for anaesthetist-led services, including focused transthoracic echocardiography and management of implantable cardiac electronic devices. Anaesthetists should be encouraged to play a proactive role in pre-operative risk stratification and make timely multidisciplinary referrals if necessary. A personalised approach to pre-operative cardiac optimisation enables a safer peri-operative journey for at-risk patients undergoing major surgery.
Introduction
It is estimated that around 200 million major operations are performed every year worldwide [1] . Overall complication rates vary among different countries but are probably around 10% [2] , with cardiac complications now one of the leading causes of all morbidity and mortality [3, 4] , accounting for 40% of postoperative mortality in one study utilising troponin levels [3] . Major adverse cardiac events comprise: acute myocardial ischaemia or infarction; angina; congestive heart failure; atrioventricular block; arrhythmias; and cardiac arrest [5] . This has a significant impact on immediate and long-term prognosis, and adds to the burden on the healthcare system by increasing the utilisation of intensive care facilities, drugs and equipment and prolonging the length of hospital stay [6, 7] .
Thorough assessment of cardiac morbidity is particularly important for high-risk surgical patients.
Although many risk scoring systems are available, the most validated one is the revised cardiac risk index, which consists of one procedural and five clinical risk factors (Table 1) [8] . A systematic review has proven a linear relationship between the score and the likelihood of perioperative cardiac complications [9] , but it is still debatable as to whether at-risk patients can benefit from such stratification approaches.
Surgical patients present with various cardiac
conditions and the peri-operative management strategies are, therefore, diverse. The common ones are addressed below. The level of evidence and the strength of recommendation of particular management options are graded according to a pre-defined scale (Table 2) .
Hypertension
Hypertension alone is only a minor independent risk factor for adverse cardiac events in non-cardiac surgery [10] , but patients with uncontrolled hypertension tend to have volatile intra-operative blood pressure which can increase risk. In the context of isolated hypertension, delaying or cancelling surgery for additional cardiac testing is usually neither necessary nor desirable. The potential benefit of delaying surgery for optimisation must be weighed against the risks of postponing surgery. Despite the availability of guidelines that recommend elective surgery should not be deferred if the blood pressure is below 180 mmHg systolic and 110 mmHg diastolic [11] , cancellation of surgery due to 'suboptimal' peri-operative control of hypertension is still encountered occasionally. The American College of Cardiology (ACC) and American Heart Association (AHA) published an updated guideline in 2017 on the definition of hypertension (Table 3) and recommendations for hypertensive patients undergoing surgical interventions (Table 4 ) [12] .
Treatment of pre-operative hypertension can be complicated, and the condition is further compounded by the phenomena known as 'masked hypertension' and 'white coat hypertension' [13, 14] . White coat hypertension is an elevated blood pressure in the clinical setting with a normal pressure at home. Masked hypertension is defined as a normal blood pressure in the clinic, but an elevated blood pressure out of the clinic. It may occur in as much as 10% of the general population, and is important because it is not diagnosed by routine medical examinations, but carries an adverse prognosis, both in terms of increased target organ damage and cardiovascular events. Patients are frequently relatively young and male, with stress or increased physical activity during the daytime, and are often smokers or have excessive alcohol consumption. Masked hypertension has also been described in treated hypertensive patients and in Table 1 Revised cardiac risk index [8] .
Risk factor Points
Cerebrovascular disease 1 There is a wide range of medications available to reduce blood pressure to the desired target before surgery.
Hypertensive subjects have more arterial pressure lability intra-operatively, although this has not been shown to be associated with increased 30-day mortality [15] .
Anaesthetists can monitor intra-operative haemodynamic fluctuation either directly or indirectly and have a range of drugs at their disposal to maintain blood pressure within an acceptable range. Anaesthetic drugs will also affect blood pressure but should only be used to maintain an optimum depth of anaesthesia, not to control blood pressure.
Therefore, it is the treatment of cardiovascular risk, not hypertension per se, that is important.
Nowadays, anaesthetists have more opportunity to assess and optimise hypertension in the outpatient assessment clinic before surgery. Firstly, the patient's baseline blood pressure should be determined, either by checking their self-monitoring record, or the record from their primary care physician [11] . If long-standing hypertension is suspected, there should be an assessment of possible end-organ damage including left ventricular hypertrophy, diastolic dysfunction, atherosclerotic coronary artery disease, heart failure, glomerular injury, renal tubular ischaemia and end-stage renal failure [16] .
For patients with systolic blood pressure < 180 mmHg and diastolic blood pressure < 110 mmHg, antihypertensives should be continued in the peri-operative period [11] . In patients with planned elective major surgery and a documented systolic pressure of ≥ 180 mmHg or diastolic pressure of ≥ 110 mmHg, surgery should be postponed [12] , and blood pressure-lowering treatment should be discussed and commenced by following the National Institute for Health and Care Excellence/British Heart Society CG127 algorithm [11] . In particular, patients with diastolic pressure ≥ 110 mmHg immediately before surgery have been shown to have increased risk of complications including myocardial infarction and renal failure [17] .
Earlier clinical trials alluded to a possible beneficial effect of beta-blockers in prevention of peri-operative cardiac risks [18, 19] . However, the peri-operative ischemic evaluation (POISE) trial and a subsequent meta-analysis showed that although initiation of beta-blockers one day or less in patients before non-cardiac surgery will decrease rates of nonfatal myocardial infarction, it paradoxically increases the risk of stroke, hypotension, bradycardia and death [20, 21] . The POISE trial was criticised for not using a titrated dose of beta-blocker, because initiating and titrating beta-blockers to heart rate weeks before surgery Table 2 ); DBP, diastolic blood pressure; SBP, systolic blood pressure.
has been advocated as there is significant pharmacogenetic variability in response [22] . Table 5 summarises the current recommendations for peri-operative beta-blocker therapy [23, 24] . However, this strategy is limited by the timing of assessment before surgery [25] .
Step-wise titration of betablockers in the pre-anaesthetic clinic allows optimisation of blood pressure and heart rate control, which may reduce peri-operative adverse cardiac events without increasing other risks [26] . Patients on chronic treatment with beta-blockers for ischaemic heart disease, arrhythmias or hypertension should be maintained on this medication throughout the peri-operative period (Class I recommendation) [23, 24] .
There is some controversy over whether it is appropriate to continue angiotensin-converting enzyme inhibitors/angiotensin-II receptor blockers in the perioperative period. There is an increased risk of intraoperative hypotension when they are continued [27, 28] and clinically-significant hypotension is independently associated with increased myocardial infarction, stroke and death, leading to the recommendation towards withholding them at least 24 h before major surgery [12, 21, 29, 30] .
However, other studies show conflicting results with no sufficient available evidence to recommend discontinuing the drugs on the day of surgery [31] [32] [33] . Anaesthetists should be aware of the potential risk of intra-operative hypotension in patients receiving the drugs and be prepared to manage it [33] . In patients on chronic treatment, it is reasonable to continue them under supervision (Class IIa recommendation) [23, 24] . Likewise, if the drugs are discontinued before surgery for fear of intraoperative hypotension, it is reasonable to resume them after surgery as soon as possible (Class IIa recommendation) [23, 24] .
Calcium channel blockers should be continued. There is little evidence to support their initiation pre-operatively for cardioprotection and, in a meta-analysis of studies investigating this, most of the benefits shown were attributed to diltiazem [34] .
Alpha-2 agonists reduce central sympathetic activity and peripheral noradrenaline release, which can attenuate the adrenergic stress response to surgery, and the reduction in heart rate can improve myocardial oxygen balance. A meta-analysis had suggested that alpha-2 agonists reduce mortality and myocardial infarction after vascular surgery [35] but another meta-analysis, restricted to dexmedetomidine, did not show a significant improvement in cardiac outcomes, although hypotension and bradycardia were increased [36] . The more definitive POISE-2 trial suggests that alpha-2 agonists should probably not be used for 'cardioprotection' in non-cardiac surgery [37] , and this opinion is reflected in the most recent guidelines from North American and European bodies (Class III recommendation) [23, 24] .
Nitrates are known to attentuate myocardial ischaemia.
However, a 2016 Cochrane systematic review found no role for any preparation of nitrate in the prevention of perioperative cardiac events, although only 3 trials recruiting a total of 149 patients, reported the all-cause mortality at 30 days [38] . To date, prophylactic use of nitrates is not recommended, as they may pose a significant risk with preload reduction [23] . A general approach for peri-operative management in the high-risk population would be to advise the patient to continue usual doses as needed, especially in case of symptom control in angina pectoris. No guidelines have been published concerning this topic.
At present, the recommended frequency of blood pressure monitoring varies hugely among different international guidelines, ranging from every primary care
visit to every 5 years [39] [40] [41] . A specialist-led pre-operative assessment clinic [42] provides opportunity to stratify patients based on risks, to make timely referrals and prescribe medications according to latest ACC/ESC guidelines [23, 24] . The referring physician should be informed for patients with newly diagnosed hypertension.
Chronic heart failure
Heart failure is a global problem, with at least 26 million people affected [43, 44] . The prevalence of heart failure is also increasing as the population ages, and more patients with congestive heart failure will present for surgery [45] .
Ejection fraction is the stroke volume divided by the enddiastolic volume and can be used in classification. Current terminology distinguishes: heart failure with preserved ejection fraction; heart failure with mid-range ejection fraction; and heart failure with reduced ejection fraction, based on the ejection fraction, natriuretic peptide levels and the presence of structural heart disease and diastolic dysfunction [46] (Table 6) .
When assessing these patients, a detailed history and clinical examination are crucial to determine the cause and quantify its severity (Tables 7 and 8 ). Patients with current or previous history of heart failure are well known to have more peri-operative complications and this is an independent prognostic variable for all cardiac risk scores [8] . There is no high-quality evidence on the use of routine pre-operative chest radiography and it is not mandatory in patients with stable chronic heart failure [47] . Resting echocardiography is also not routinely recommended in patients with chronic and stable heart failure [50] . However, patients with signs and symptoms of worsening heart failure require investigations to assess the severity of systolic or diastolic dysfunction which will guide peri-operative management. In patients with acutely decompensated heart failure (New York Heart Association class IV), surgery should be postponed, if possible, and the opinion of a cardiologist sought for titration of heart failure medication [24] . Cardiac biomarkers have been used to predict the risk There is a growing body of evidence supporting outcome improvements in patients with better overall physical condition. Guidelines for the diagnosis and treatment of acute and chronic heart failure recommend supervised aerobic exercises to improve functional status and reduce the risk of hospital admission [46] . The evidence comes mostly from patients with heart failure and a reduced ejection fraction. The HF-ACTION trial is the largest multicentre, randomised controlled trial so far to look at the efficacy and safety of aerobic exercise training among patients with heart failure; it enrolled more than 2000 patients [62] . For the primary composite end-point of allcause mortality or all-cause hospitalisation, there was no significant difference between supervised exercise training and usual care (education and recommendation of regular exercise). However, after adjustment for prognostic baseline variables, there was a significant but modest reduction in all-cause mortality or all-cause hospitalisation in the exercise training group [62] . Other studies have shown improvements in functional status and quality of life after exercise training in patients with heart failure with reduced ejection fraction [63, 64] . In addition, it has been demonstrated that exercise training improves peak oxygen The diagnosis of heart failure requires that either two major or one major and two minor criteria are met. Class IV Unable to carry on any physical activity without discomfort. Symptoms at rest. If any physical activity is undertaken, discomfort is increased Table 9 Cardiac risk stratification for non-cardiac surgical procedures [110] . uptake in patients with heart failure [64] [65] [66] . Apart from that, it improves cardiac structure and function, with significant improvements in left ventricular ejection fraction, enddiastolic and end-systolic volumes observed in patients receiving aerobic exercise training [67] .
Risk of procedure Examples
The clinical significance of cardiac rehabilitation is well described, especially in patients with heart failure. However, there is limited research about the use of pre-operative rehabilitation, also known as pre-habilitation, in this patient group. Preliminary evidence shows that pre-operative supervised exercise training enhances postoperative outcome in terms of shorter hospital stay and fewer postoperative complications [68, 69] . A systematic review has shown that pre-operative aerobic exercise training is effective in improving physical fitness in patients planned for intra-abdominal and intrathoracic surgery [70] .
Pre-habilitation may well have a useful role but further largescale studies will be needed to determine the best type of training to be prescribed for surgical patients with underlying heart failure. First of all, at-risk patients should be identified, and functional capacity and frailty are components of pre-operative evaluation. Biccard [71] provides evidence for predicting peri-operative complications associated with major non-cardiac surgery using stair-climbing capacity (four metabolic equivalents).
Type of exercise and its duration is, as yet, undefined. It would be reasonable to initiate pre-habilitation during the waiting period for elective surgery, as patients tend to have little physical activity while waiting [72] [73] [74] . The PREHAB study [75] , which hypothesises that an interdisciplinary pre-operative programme composed of an 8-week comprehensive exercise therapy and education programme will improve postoperative clinical outcome of frail elderly patients awaiting elective cardiac surgery, is still ongoing and results are expected to be released this year.
Cardiac murmurs
Systolic cardiac murmurs are common. In a study on an unselected cohort of elderly patients with fractured neck of femur, 30% had mild aortic stenosis or aortic sclerosis and 8% were found to have either moderate or severe aortic stenosis [76] . Yet, clinical examination alone is neither sensitive nor specific for evaluating undifferentiated murmurs, and valvular lesions are often missed with auscultation [77, 78] . In particular, it is unreliable in diagnosing combined disease in the aortic and mitral valves with a sensitivity of 55%, even in experienced hands [77] .
The ability to detect diastolic heart murmurs is even worse, especially in the presence of a systolic murmur, with a sensitivity of only 20-40% [77, 79] .
Previously undetected cardiac murmurs are commonly found during pre-operative assessment [80, 81] and are among the most common reasons for referral to a cardiologist [82] . A comprehensive history and physical examination remains the cornerstone of assessment.
Recently, especially with cheaper and more portable ultrasound devices, there has been an expansion of echocardiography use in the peri-operative period among anaesthetists [83] [84] [85] [86] . This, however, also has created challenges. Ideally, operations should be postponed while waiting for formal echocardiography, which may be undesirable, especially in emergencies. In a patient presenting with an otherwise asymptomatic cardiac murmur, although it would be useful to have transthoracic echocardiography to exclude cardiac pathology, such expertise may not always be readily accessible. Fortunately, training in, and utilisation of, pre-operative focused transthoracic echocardiography is becoming more available to anaesthetists [87, 88] . The examination is noninvasive and can be completed within 10 min in an outpatient setting. It allows the detection of significant valvular lesions, assessment of left and right ventricular function and detection of pericardial effusion [84] . It has been shown that even relatively junior anaesthetists can diagnose aortic stenosis, and assess its severity, after limited training [89] .
There is now widespread use of echocardiography in patient assessment and management [90] , and recent studies on the impact of focused transthoracic echo in pre-operative assessment [91, 92] . In general, no device reprogramming is required for surgery below the umbilicus [103] . When reprogramming is required, it is usually performed by trained personnel with a device-specific programming machine. Classic teaching describes placing a magnet onto the device for temporary suspension of the function of cardiac implantable electronic devices, however, this approach is seldom employed nowadays. The responses of the different devices to the magnet vary and are, thus, unpredictable, but it is also challenging to keep it in the optimal position particularly, when the surgery is performed in the lateral or prone position. In circumstances when placing a magnet is required, it is crucial to clarify with the cardiologist what will be the exact response of the cardiac implantable electronic device [104] . The British Society of Heart Rhythm has published a guide on the actions required for device management during different clinical scenarios (Table 10) [107]. These scenarios can be diverse and there is a paucity of evidence for peri-operative management of these devices for every specific procedure. As mentioned above, it is still advisable to discuss with the parent team for patients either with a complex device implanted or those with complicated cardiac conditions.
Conclusion
Many of the conditions mentioned above can be optimised before surgery and, therefore, to some extent can be regarded as modifiable risk factors. Anaesthetists can play an important role both in stratifying the risks and in initiating or titrating management, as well as liaising with other specialists where appropriate. Ultimately, the objective of pre-operative cardiac optimisation is to identify and modify these conditions well in advance to avoid cancellation or postponement of surgery and reduce the likelihood of perioperative complications. 
